Skip to main navigation Skip to search Skip to main content

Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib

N. Von Bubnoff*, C. Rummelt, H. Menzel, M. Sigl, C. Peschel, J. Duyster

*Corresponding author for this work
Original languageEnglish
JournalLeukemia
Volume24
Issue number8
Pages (from-to)1523-1525
Number of pages3
ISSN0887-6924
DOIs
Publication statusPublished - 08.2010

Funding

Institut National du Cancer. This work was supported by grants from the Ligue Nationale Contre le Cancer (équipe labelisée 2009). This letter is dedicated to Sabrina Dupont whose work greatly contributed to the discovery of TET2 mutations in MPNs. This work was supported by Bundesministerium für Bildung und Forschung grant NGFNplus 01GS0878.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this